onr:"swepub:oai:DiVA.org:liu-206612"
Sökning: onr:"swepub:oai:DiVA.org:liu-206612" > Changes in lean bod...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies
-
- Neeland, Ian J. (författare)
- Case Western Reserve Univ, OH USA; Univ Hosp Cleveland Med Ctr, OH USA
-
- Linge, Jennifer (författare)
- Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,AMRA Med AB, Linkoping, Sweden
-
- Birkenfeld, Andreas L. (författare)
- Eberhard Karls Univ Tubingen, Germany; German Ctr Diabet Res DZD, Germany; Eberhard Karls Univ Tubingen, Germany; Kings Coll London, England
- (creator_code:org_t)
- 2024
- 2024
- Engelska.
- Ingår i: Diabetes, obesity and metabolism. - : WILEY. - 1462-8902 .- 1463-1326.
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor agonists is coming closer to the magnitudes achieved with surgery. However, with greater weight loss there is concern about potential side effects on muscle quantity (mass), health and function. There is heterogeneity in the reported effects of GLP-1-based therapies on lean mass changes in clinical trials: in some studies, reductions in lean mass range between 40% and 60% as a proportion of total weight lost, while other studies show lean mass reductions of approximately 15% or less of total weight lost. There are several potential reasons underlying this heterogeneity, including population, drug-specific/molecular, and comorbidity effects. Furthermore, changes in lean mass may not always reflect changes in muscle mass as the former measure includes not only muscle but also organs, bone, fluids, and water in fat tissue. Based on contemporary evidence with the addition of magnetic resonance imaging-based studies, skeletal muscle changes with GLP-1RA treatments appear to be adaptive: reductions in muscle volume seem to be commensurate with what is expected given ageing, disease status, and weight loss achieved, and the improvement in insulin sensitivity and muscle fat infiltration likely contributes to an adaptive process with improved muscle quality, lowering the probability for loss in strength and function. Nevertheless, factors such as older age and severity of disease may influence the selection of appropriate candidates for these therapies due to risk of sarcopenia. To further improve muscle health during weight loss, several pharmacological treatments to maintain or improve muscle mass designed in combination with GLP-1-based therapies are under development. Future research on GLP-1-based and other therapies designed for weight loss should focus on more accurate and meaningful assessments of muscle mass, composition, as well as function, mobility or strength, to better define their impact on muscle health for the substantial number of patients who will likely be taking these medications well into the future.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Fysiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Physiology (hsv//eng)
Nyckelord
- cardiovascular disease; GLP-1 receptor agonist; insulin resistance; muscle; obesity; sarcopenia; type 2 diabetes
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
- Diabetes, obesity and metabolism (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Neeland, Ian J.
- Linge, Jennifer
- Birkenfeld, Andr ...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Medicinska och f ...
- och Fysiologi
- Artiklar i publikationen
- Diabetes, obesit ...
- Av lärosätet
- Linköpings universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
